Serotonin 5-HT3 Receptor Antagonists
"Serotonin 5-HT3 Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate SEROTONIN 5-HT3 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT3 RECEPTOR AGONISTS.
| Descriptor ID |
D058831
|
| MeSH Number(s) |
D27.505.519.625.850.850.300 D27.505.696.577.850.850.300
|
| Concept/Terms |
Serotonin 5-HT3 Receptor Antagonists- Serotonin 5-HT3 Receptor Antagonists
- Serotonin 5 HT3 Receptor Antagonists
- 5-HT3 Antagonist
- 5 HT3 Antagonist
- Antagonist, 5-HT3
- 5-HT3 Antagonists
- 5 HT3 Antagonists
- Antagonists, 5-HT3
|
Below are MeSH descriptors whose meaning is more general than "Serotonin 5-HT3 Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Serotonin 5-HT3 Receptor Antagonists".
This graph shows the total number of publications written about "Serotonin 5-HT3 Receptor Antagonists" by people in this website by year, and whether "Serotonin 5-HT3 Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Serotonin 5-HT3 Receptor Antagonists" by people in Profiles.
-
High-flow oxygen and pro-serotonin agents for non-interventional treatment of post-dural-puncture headache. Am J Emerg Med. 2020 12; 38(12):2625-2628.
-
Nausea and vomiting: Therapeutic orphans of pediatric oncology. Pediatr Blood Cancer. 2017 10; 64(10).
-
Expression of gLTP in sympathetic ganglia of obese Zucker rats in vivo: molecular evidence. J Mol Neurosci. 2008 Jul; 35(3):297-306.
-
Psychosocial stress-induced hypertension results from in vivo expression of long-term potentiation in rat sympathetic ganglia. Neurobiol Dis. 2005 Dec; 20(3):849-57.
-
A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res. 2004 Nov 15; 10(22):7450-6.